Letter: When less is more: Dexamethasone dosing for brain tumors

Mary Jane Lim-Fat; Wenya Linda Bi; Janet Lo; Eudocia Quant Lee; Manmeet S. Ahluwalia; Tracy T. Batchelor; Susan M. Chang; E. Antonio Chiocca; Ugonma Chukwueke; Timothy F. Cloughesy; Howard Colman; Lisa M. Deangelis; Evanthia Galanis; Mark R. Gilbert; John F. De Groot; Andrew B. Lassman; Linda M. Liau; Warren Mason; J. Ricardo McFaline-Figueroa; Minesh P. Mehta; Ingo K. Mellinghoff; L. Burt Nabors; Lakshmi Nayak; David A. Reardon; Patrick Y. Wen

doi:10.1093/neuros/nyz186

Letter: When less is more: Dexamethasone dosing for brain tumors

Mary Jane Lim-Fat, Wenya Linda Bi, Janet Lo, Eudocia Quant Lee, Manmeet S. Ahluwalia, Tracy T. Batchelor, Susan M. Chang, E. Antonio Chiocca, Ugonma Chukwueke, Timothy F. Cloughesy, Howard Colman, Lisa M. Deangelis, Evanthia Galanis, Mark R. Gilbert, John F. De Groot, Andrew B. Lassman, Linda M. Liau, Warren Mason, J. Ricardo McFaline-Figueroa, Minesh P. MehtaIngo K. Mellinghoff, L. Burt Nabors, Lakshmi Nayak, David A. Reardon, Patrick Y. Wen

Medical Oncology

Research output: Contribution to journal › Letter › peer-review

5 Scopus citations

Original language	English (US)
Article number	nyz186
Pages (from-to)	E607-E608
Journal	Clinical neurosurgery
Volume	85
Issue number	3
DOIs	https://doi.org/10.1093/neuros/nyz186
State	Published - Sep 1 2019

ASJC Scopus subject areas

Surgery
Clinical Neurology

Access to Document

10.1093/neuros/nyz186

Cite this

Lim-Fat, M. J., Bi, W. L., Lo, J., Lee, E. Q., Ahluwalia, M. S., Batchelor, T. T., Chang, S. M., Chiocca, E. A., Chukwueke, U., Cloughesy, T. F., Colman, H., Deangelis, L. M., Galanis, E., Gilbert, M. R., De Groot, J. F., Lassman, A. B., Liau, L. M., Mason, W., McFaline-Figueroa, J. R., ... Wen, P. Y. (2019). Letter: When less is more: Dexamethasone dosing for brain tumors. Clinical neurosurgery, 85(3), E607-E608. Article nyz186. https://doi.org/10.1093/neuros/nyz186

Lim-Fat, MJ, Bi, WL, Lo, J, Lee, EQ, Ahluwalia, MS, Batchelor, TT, Chang, SM, Chiocca, EA, Chukwueke, U, Cloughesy, TF, Colman, H, Deangelis, LM, Galanis, E, Gilbert, MR, De Groot, JF, Lassman, AB, Liau, LM, Mason, W, McFaline-Figueroa, JR, Mehta, MP, Mellinghoff, IK, Nabors, LB, Nayak, L, Reardon, DA & Wen, PY 2019, 'Letter: When less is more: Dexamethasone dosing for brain tumors', Clinical neurosurgery, vol. 85, no. 3, nyz186, pp. E607-E608. https://doi.org/10.1093/neuros/nyz186

@article{c90221702c01476fa28b12452066c9fe,

title = "Letter: When less is more: Dexamethasone dosing for brain tumors",

author = "Lim-Fat, {Mary Jane} and Bi, {Wenya Linda} and Janet Lo and Lee, {Eudocia Quant} and Ahluwalia, {Manmeet S.} and Batchelor, {Tracy T.} and Chang, {Susan M.} and Chiocca, {E. Antonio} and Ugonma Chukwueke and Cloughesy, {Timothy F.} and Howard Colman and Deangelis, {Lisa M.} and Evanthia Galanis and Gilbert, {Mark R.} and {De Groot}, {John F.} and Lassman, {Andrew B.} and Liau, {Linda M.} and Warren Mason and McFaline-Figueroa, {J. Ricardo} and Mehta, {Minesh P.} and Mellinghoff, {Ingo K.} and Nabors, {L. Burt} and Lakshmi Nayak and Reardon, {David A.} and Wen, {Patrick Y.}",

note = "Funding Information: Dr Colman is on the Advisory Board for and is a consultant for Abbvie, Foundation Medicine, Innocrin, Tactical Therapeutics, Deciphera, Newlink Genetics, Best Doctors, Merck, and Karyopharm Therapeutics, and receives research funding (Site PI/Institutional Contract): Newlink Genetics, Plexxikon, Kadmon, Orbus, Merck, DNATrix, Abbvie, Beigene, and Forma. Dr Lo is on the Advisory Board for Gilead Sciences and is a consultant for Viiv Healthcare. Dr Mellinghoff receives research funding from General Electric, Amgen, and Lilly, has advisory roles with Agios, Puma Biotechnology, and Debiopharm Group, and has received honoraria from Roche for a presentation. Dr Mehta is a consultant for Varian, Abbvie, Celgene, Astra-Zeneca, Tocagen, and Blue Earth Diagnostics, and is on the Board of Directors for Oncoceutics. Dr Lassman has received honoraria/travel/research support (prior 12 mo, all outside the submitted work) from Karyopharm, NW Bio, Agios, AbbVie, Sapience, Oncoceutics, Novocure, Tocagen, Genentech/Roche, Amgen, Millenium, Celldex, Novartis, Pfizer, Aeterna Zentaris, Pfizer, Kadmon, VBI Vaccines, Beigene, and Bioclinica. Dr Ahluwalia has received grants/research support from Astrazeneca, Abbvie, BMS, Bayer, Incyte, Pharmacyclics, Novocure, and Merck, has received honoraria or consultation fees from Elsevier, Wiley, Astrazeneca, Abvvie, VBI Vaccines, Flatiron, Varian Medical Systems, and Prime Education, and is a stock shareholder in Doctible and Mimiva.",

year = "2019",

month = sep,

day = "1",

doi = "10.1093/neuros/nyz186",

language = "English (US)",

volume = "85",

pages = "E607--E608",

journal = "Clinical neurosurgery",

issn = "0148-396X",

publisher = "Lippincott Williams and Wilkins",

number = "3",

}

TY - JOUR

T1 - Letter

T2 - When less is more: Dexamethasone dosing for brain tumors

AU - Lim-Fat, Mary Jane

AU - Bi, Wenya Linda

AU - Lo, Janet

AU - Lee, Eudocia Quant

AU - Ahluwalia, Manmeet S.

AU - Batchelor, Tracy T.

AU - Chang, Susan M.

AU - Chiocca, E. Antonio

AU - Chukwueke, Ugonma

AU - Cloughesy, Timothy F.

AU - Colman, Howard

AU - Deangelis, Lisa M.

AU - Galanis, Evanthia

AU - Gilbert, Mark R.

AU - De Groot, John F.

AU - Lassman, Andrew B.

AU - Liau, Linda M.

AU - Mason, Warren

AU - McFaline-Figueroa, J. Ricardo

AU - Mehta, Minesh P.

AU - Mellinghoff, Ingo K.

AU - Nabors, L. Burt

AU - Nayak, Lakshmi

AU - Reardon, David A.

AU - Wen, Patrick Y.

N1 - Funding Information: Dr Colman is on the Advisory Board for and is a consultant for Abbvie, Foundation Medicine, Innocrin, Tactical Therapeutics, Deciphera, Newlink Genetics, Best Doctors, Merck, and Karyopharm Therapeutics, and receives research funding (Site PI/Institutional Contract): Newlink Genetics, Plexxikon, Kadmon, Orbus, Merck, DNATrix, Abbvie, Beigene, and Forma. Dr Lo is on the Advisory Board for Gilead Sciences and is a consultant for Viiv Healthcare. Dr Mellinghoff receives research funding from General Electric, Amgen, and Lilly, has advisory roles with Agios, Puma Biotechnology, and Debiopharm Group, and has received honoraria from Roche for a presentation. Dr Mehta is a consultant for Varian, Abbvie, Celgene, Astra-Zeneca, Tocagen, and Blue Earth Diagnostics, and is on the Board of Directors for Oncoceutics. Dr Lassman has received honoraria/travel/research support (prior 12 mo, all outside the submitted work) from Karyopharm, NW Bio, Agios, AbbVie, Sapience, Oncoceutics, Novocure, Tocagen, Genentech/Roche, Amgen, Millenium, Celldex, Novartis, Pfizer, Aeterna Zentaris, Pfizer, Kadmon, VBI Vaccines, Beigene, and Bioclinica. Dr Ahluwalia has received grants/research support from Astrazeneca, Abbvie, BMS, Bayer, Incyte, Pharmacyclics, Novocure, and Merck, has received honoraria or consultation fees from Elsevier, Wiley, Astrazeneca, Abvvie, VBI Vaccines, Flatiron, Varian Medical Systems, and Prime Education, and is a stock shareholder in Doctible and Mimiva.

PY - 2019/9/1

Y1 - 2019/9/1

UR - http://www.scopus.com/inward/record.url?scp=85071355687&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071355687&partnerID=8YFLogxK

U2 - 10.1093/neuros/nyz186

DO - 10.1093/neuros/nyz186

M3 - Letter

C2 - 31215634

AN - SCOPUS:85071355687

SN - 0148-396X

VL - 85

SP - E607-E608

JO - Clinical neurosurgery

JF - Clinical neurosurgery

IS - 3

M1 - nyz186

ER -

Letter: When less is more: Dexamethasone dosing for brain tumors

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this